openPR Logo
Press release

Global Sickle Cell Anemia Drug Market Price Dosage And Clinical Pipeline Outlook 2024

05-18-2018 10:41 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Sickle Cell Anemia Drug Market Price Dosage And Clinical

Download Report Sample Weblink:

https://www.kuickresearch.com/report-global-sickle-cell-anemia-drug-market-price-dosage-and-clinical-pipeline-outlook-2024.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Sickle Cell Anemia - An Inherited Blood Disorder
1.1 Introduction
1.1.1 Signs and Symptoms of Sickle Cell Anemia
1.1.2 Types of Sickle Cell Disease
1.2 Antiquity of Sickle Cell Disease

2. Genetics and Diagnostics of Sickle Cell Disease
2.1 Genetic Mutations
2.2 Diagnostic Approaches for Sickle Cell Disease
2.2.1 Blood Test
2.2.2 Prenatal Testing
2.2.3 Newborn Screening
2.3 Cost Analysis of Sickle Cell Disease Diagnosis

3. Management Strategies for Sickle Cell Disease Treatment - Cost Analysis
3.1 Medication Methods
3.2 Transfusion
3.3 Bone Marrow Transplant

4. Total Annual Cost for Patients with Sickle Cell Disease
4.1 Fees for Hospitalization, Emergency Department and Professional Fees
4.2 Annual Fees for the care of an Adult Patient with Sickle Cell Disease

5. Advance Research for Treatment of Sickle Cell Anemia Disease
5.1 Introduction
5.2 Umbilical Cord Blood Transplant
5.3 Gene Therapy

6. Sickle Cell Anemia - Drug and Treatment Cost Analysis
6.1 Glutamine (Endari)
6.2 Hydroxycarbamide (Droxia, Hydrea)
6.3 Nicosan (Niprisan or Nix-0699)
6.4 Ibuprofen

7. Market Analysis of Sickle Cell Disease
7.1 Introduction
7.2 Sickle Cell Disease Market Size

8. Global Sickle Cell Anemia Drug Market Dynamics
8.1 Favorable Parameters
8.2 Challenges

9. Future Aspects of Global Sickle Cell Disease Treatment Market

10. Global Sickle Cell Anemia Drug Clinical Pipeline by Company and Phase
10.1 Sickle Cell Anemia Drug Clinical Pipeline Overview
10.2 Research
10.3 Preclinical
10.4 Phase-I
10.5 Phase-I/II
10.6 Phase-II
10.7 Phase-III

11. Marketed Sickle Cell Anemia Drug Clinical Insight
11.1 Glutamine (Endari and NutreStore)
11.2 Hydroxycarbamide (Siklos)
11.3 Hydroxycarbamide (Droxia, Hydrea, Litalir and OncoCarbide)
11.4 Nix 0699 (Hemoxin, Nicosan and Niprisan)

12. Competitive Landscape
12.1 BioMarin
12.2 Bluebird Bio Bluebird Bio
12.3 DeuteRx
12.4 Emmaus Medical
12.5 Gamida Cell
12.6 Global Blood Therapeutics
12.7 GlycoMimetics
12.8 Modus Therapeutics
12.9 Pfizer
12.10 Sancilio Pharmaceuticals
12.11 Sangamo Biosciences

Figure 1-1: Inheritance Pattern of Sickle Cell Anemia from One Generation to Next Generation
Figure 1-2: Historical Development of Sickle Cell Disease and its Therapeutic Approaches
Figure 2-1: Genetic Mutations which Occur at the Transcription and Translational Level
Figure 2-2: Pathophysiology of Sickle Cell Disease
Figure 2-3: Various Diagnostic Methods for Sickle Cell Disease
Figure 2-4: Price Analysis - Sickle Cell Diagnosis Cost with Insurance (US$), 2018
Figure 2-5: Price Analysis - Sickle Cell Diagnosis Cost without Insurance (US$), 2018
Figure 2-6: Price Analysis - CVS and Amniocentesis for Sickle Cell Anemia(US$), 2018
Figure 2-7: Global - Average NIPT Screening Cost by Technique (US$), 2018
Figure 3-1: Several Management Approaches for Sickle Cell Disease
Figure 3-2: Sickle Cell Disease - Treatment Cost Analysis by Medication (US$/Month), 2018
Figure 3-3: Acceptable Outcomes for Sickle Cell Disease Bone Marrow Transplant
Figure 3-4: Allogeneic and Autogenic Bone Marrow Transplant Cost (US$), 2018
Figure 4-1: Consultation Fees for Sickle Cell Disease (US$/Patient), 2018
Figure 4-2: Hospitalization Charges for Sickle Cell Disease (US$/Day), 2018
Figure 4-3: Price Analysis - Emergency Department Cost (US$/Patient), 2018
Figure 4-4: Emergency Department Professional Fees Billed by Severity (US$), 2018
Figure 4-5: Price Analysis - Average Hospital Charges (US$/SCD patient), 2018
Figure 4-6: Annual Cost Analysis for Tests Involved in Sickle Cell (US$/Patient), 2018
Figure 4-7: Expenditure on SCD Patient by Age (US$/Annum), 2018
Figure 5-1: Ongoing Research for the Development of Sickle Cell Disease Treatment
Figure 5-2: Umbilical Cord Blood Transplant Method for Sickle Cell Anemia
Figure 5-3: Cost Analysis - Umbilical Cord Blood Transplant (US$/Patient), 2018
Figure 5-4: Gene Therapy Method for Sickle Cell Disease Treatment
Figure 5-5: Gene Therapy - Estimated Cost of Therapy and Medication (US$/Patient),2018
Figure 6-1: Endari - Dosage by Body Weight (gram/Dose)
Figure 6-2: Endari - Dosage per day by Body Weight (gram/Day)
Figure 6-3: Endari - Packet Consumption (Number) per Dose by Weight
Figure 6-4: Endari - Packets Consumed (Number of Packets/Day)
Figure 6-5: Endari - Price Analysis for 5mg Tablet (US$/Packet), 2018
Figure 6-6: Droxia - Available Concentrations by type (mg/Tablet)
Figure 6-7: Droxia - Dosage Analysis by Weight (mg/kg)
Figure 6-8: Droxia - Price Analysis per 60 Tablet Packet (US$), 2018
Figure 6-9: Nicosan - Recommended Dosage in children and Adult (mg/Day)
Figure 6-10: Patent Approval Year in UK and US
Figure 6-11: Ibuprofen - Availability by concentration (mg and mg/ml)
Figure 6-12: Ibuprofen - Price of 6ml Intravenous Solution Vial (US$), 2018
Figure 6-13: Ibuprofen - Oral Capsule Price Analysis (US$), 2018
Figure 6-14: Ibuprofen - Price Analysis of Oral Suspension (US$), 2018
Figure 6-15: Ibuprofen - Price Analysis of Oral Tablets (US$/Packet), 2018
Figure 7-1: Burden of Rare Diseases in US and Globally (%)
Figure 7-2: Global - Incidence of Sickle Cell Disease (%), 2018
Figure 7-3: Global - Sickle Cell Anemia Childhood Survival Rates by Region (%), 2018
Figure 7-4: Global - Orphan Drugs Market Forecast (US$ Billion), 2016 - 2024
Figure 7-5: Global - Sickle Cell Disease Market Size (%), 2018
Figure 7-6: Global - Blood Disorders Market Size by Type (%), 2018
Figure 8-1: Favorable Growth Factors for the Sickle Cell Disease Treatment
Figure 8-2: Challenges to the Growth of Sickle Cell Disease Treatment
Figure 9-1: Global - Sickle Cell Disease Market Opportunity (US$ Million), 2018 -2024
Figure 10-1: Global - Sickle Cell Anemia Drug Pipeline by Phase (%), 2018 till 2024
Figure 10-2: Global - Sickle Cell Anemia Drug Pipeline by Phase (Number), 2018 till 2024
Figure 10-3: Global - Discontinued Sickle Cell Anemia Drug Pipeline by Phase (%),2018 till 2024
Figure 10-4: Global - Discontinued Sickle Cell Anemia Drug Pipeline by Phase (Number), 2018 till 2024






Table 3-1: Clinical Trials Addressing Transfusion Indications for Sickle Cell Disease
Table 5-2: Droxia - Dosage Analysis by Weight (mg/kg)

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Sickle Cell Anemia Drug Market Price Dosage And Clinical Pipeline Outlook 2024 here

News-ID: 1054428 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Figure

Floralite - Reduce Fat & Get Attractive Figure How To Buy!
Floralite Have you been working on your eating routine without seeing the results that you are anticipating? There is indeed thing called Floralite diet pills. Advantages of Floralite Floralite One of various things to esteem about this thing is that it's made expressly for the Floralite diet. That is an epic notwithstanding considering the way that when you use a thing that is custom fitted to work with the movements
THE WORLD'S MOST CONTROVERSIAL ACTION FIGURE...EVER!
FOR IMMEDIATE RELEASE THE WORLD'S MOST CONTROVERSIAL ACTION FIGURE...EVER! Contact: William Hirsch - Schlock Toys @ +1-949-677-9353 or DocSchlock@SchlockToys.com Featured on Tomi with Fox News host Tomi Lahren! SCHLOCK TOYS join forces with Kickstarter to Make Toys Great Again! The Kickstarter campaign page can be found HERE: https://www.kickstarter.com/projects/schlocktoys/collectors-edition-talking-trump-2020-man-of-action-figure/description “What a great message to be sent, and I think Trump himself would love this and that he’d be excited about it!” - Tomi Lahren, Fox News “You
Macarons Market Latest Sales Figure Signals More Opportunities Ahead
Global Macarons Sales Market(Sales,Revenue and competitors Analysis of Major Market)from 2014-2026 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Macarons Market. Some of the key players profiled in the study are La Dure,
Global Womens Figure Skates Market Growth 2019-2024
LP INFORMATION offers a latest published report on Womens Figure Skates Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Womens Figure Skates market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.
Figure Skating Equipment Market Report 2018: Segmentation by Type (Figure Skate …
Global Figure Skating Equipment market research report provides company profile for SP-Teri, Graf Skate, Riedell Shoes, Roces, American Athletic, Rollerblade, Winnwell, Dongguan King Line, Jackson Ultima, HD Sports(MK Blades, John Wilson), Edea, Risport Skates, Paramount Skates and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY
Long-lasting Performance Improvement with Key Figure Analysis
Vienna/Reutlingen, October 17, 2012 – Manz, a leading high-tech mechanical engineering company, is optimizing its processes in strategic sourcing in order to recognize the risks and potential associated with each supplier early on so that the sourcing department can react to them in time. POOL4TOOL’s customized eSolutions localize and analyze key figures that are relevant to the decision making process, and displays these figures in a comprehensive and transparent way.